Pfizer pipeline update Generic Learn the difference Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. Regulatory Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 29 Phase 2 38 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of January 29, 2019. U. Cachexia is a If you are a Health Care Professional and interested in further details (including pathways being explored, mechanisms of action of investigational compounds, and an overall summary of investigational compounds organized by therapy area and disease state), please visit our in-depth Pfizer Immunology & Inflammation Research Pipeline site. The information contained last update Pfizer Pipeline Snapshot as of November 6, 2014 Pfizer Pipeline Snapshot as of August 7, 2014 Registration Recent Approval -Eliquis for Venous Thromboembolism identified in this list. 0 Billion in Pipeline represents progress of R&D programs since 8/11/11 Included are 72 NMEs plus 23 additional indications 12 12 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of November 10, 2011 Recent Approvals-Xalkori (crizotinib) for ALK-Positive Non-Small Cell Lung Cancer (U. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small Pfizer expects sales of Comirnaty, the Covid vaccine it developed with German company BioNTech, and its antiviral pill Paxlovid, to fall 62 per cent to $21. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Type PF pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant last update Pfizer Pipeline Snapshot as of May 2, 2017 Pfizer Pipeline Snapshot as of January 31, 2017 Registration Recent Approvals -Bavencio (avelumab) for Merkel Cell Carcinoma (US) -Xeljanz (tofacitinib) for Rheumatoid Arthritis (EU) With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. Phase of Development. last update Pfizer Pipeline Snapshot as of July 28, 2015 Pfizer Pipeline As of January 31, 2017, Pfizer’s pipeline from Phase 1 to registration is comprised of 96 investigational therapies. Pfizer Pipeline as of January 31, transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Programs Discontinued Since Last Update 14 Backup: Regulatory Designation Definitions 15-16. This webcast may contain forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans and With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant At Pfizer Oncology, we are at the forefront of a new era in cancer care. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study Company unveils new innovative Oncology organization, strategic vision and approach, following the Seagen acquisition in late 2023 Robust portfolio and R&D engine with 8+ potential blockbuster medicines by 2030 Multiple near- and mid-term catalysts expected to help drive long-term sustainable growth At a meeting with the investment community today, Pfizer Update on Pfizer's Phase 2 Second Generation Influenza Vaccine Trial. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Forward-Looking Statements of Pfizer Inc. EXECUTIVE COMMENTARY. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Exploring the Pipeline: A glimpse behind the numbers. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant (BUSINESS WIRE)--Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company’s growth, productivity and performance goals. Pfizer Pipeline represents progress of R&D programs as of January 30, 2018 Included are 56 NMEs, 24 additional indications, plus 7 biosimilars 14 projects discontinued since last update Phase 2 Phase 3 38 19 28 10 Phase 1 Total 95 Discovery Projects 10 programs advanced or are new 1 project discontinued since last update Pfizer Pipeline (BUSINESS WIRE)--Pfizer Inc today provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials for two new molecular entities. The information contained on these pages is correct as of October 30, 2018. Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other immunotherapy biologics. PF-07265807, an AXL/MER inhibitor, had entered the clinic in 2020 and was being evaluated in a first-in-human trial in selected advanced solid tumours. Executives Our senior-most leadership ; Board Members The people steering our company ; Scientists Our experts making discoveries ; Patient Stories Our patients ; Colleague Stories Our colleagues ; Responsibility. The number in late-stage (Phase 3) development has grown from 16 to 25 over the past six This release contains forward-looking information about Pfizer’s potential future development of once-daily formulation of danuglipron, an investigational oral GLP-1 receptor agonist, including its potential benefits and a planned dose optimization study of the preferred formulation to inform the registration enabling studies, as well as Pfizer’s pipeline of clinical expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. In total, the company initiated seven Phase 3 programs within the past six months. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant last last update update Pfizer Pipeline Snapshot as of February 28, 2012 Recent Approvals-Vyndaqel (tafamidis meglumine) for treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy (EU)-Prevnar 13 Adult for prevention of lidii 4 Pipeline represents progress of R&D programs as of 11/10/11 Included are the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent last update Pfizer Pipeline Snapshot as of August 7, 2014 Pfizer Pipeline Snapshot as of May 8, 2014 Registration Recent Approval -Eliquis for Venous Thromboembolism Prevention (US) Recent Approval -Eliquis for Venous Thromboembolism the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent last last update update Pfizer Pipeline Snapshot as of August 9, 2012 Recent Approval-Lyrica for treatment of central neuropathic pain due to spinal cord injury 4 Pipeline represents progress of R&D programs as of May 10, 2012 Included are 64 NMEs, the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. 95. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. 11. The information contained on these pages is Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron KP. Dr. Learn more about how our pipeline is driving our Global Business and find out how Pfizer is collaborating with peers, industry and third parties to fill our pipeline with potential therapies that meet the needs of patients today. Updated as of October 29, 2024. 80 to $3. You’ve probably heard the industry statistics: On average it takes nearly a decade to produce a new An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). Full-Year 2025 Revenue Guidance (1) Range of $61. Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 last last update update Pfizer Pipeline Snapshot as of May 10, 2012 Recent Approvals-ELELYSO (taliglucerase alpha) for treatment of adults with a confirmed diagnosis of type 1 Gaucher disease (U. For the last decade, Pfizer’s biosimilars – high-quality, highly similar versions of reference biologic medicines – have been delivering on the Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 Forward-Looking Statements of Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. 5bn in 2023, compared to last year. The information contained on these pages is correct as of October 27, 2015. Category: Finance Media Contact: Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9. 26. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Oncology Drug Pipeline & Cancer Clinical Trials. Clinical Phase 1/2 study results Pfizer’s Oncology pipeline has the potential to deliver up to 14 approvals expected by the end of 2025 and the potential for 24 new molecular entities in the clinic by the end of 2021. Pfizer business executives and scientific leadership will provide updates on the last last update update Pfizer Pipeline Snapshot as of February 28, 2013 Recent Approval-Eliquis for Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U. 26 3535 18 18 11 Phase 1 With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. The pipeline now includes 114 programs, from Phase 1 through Registration. Financial Performance. It forecasts the 19 drug launches will generate about $20bn in annual revenues by 2030, enough to cover the hit to sales caused EMBLAVEO® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria EMBLAVEO® was reviewed under European Medicines Agency accelerated assessment Pfizer assumes no obligation to update forward-looking statements contained in this release or the webcast as the result of new information or future events or developments. (NYSE: PFE) today announced positive topline results from the The information contained in this release is as of December 17, 2021. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. 41 3636 25 25 12 Phase 1 Total 114 Discovery Projects 13 13 programs programs advanced With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. 0 to $64. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study Product Pipeline; Research Sites; Products. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. The information contained last update Pfizer Pipeline Snapshot as of April 28, 2015 Pfizer Pipeline Snapshot as of February 27, 2015 Registration Recent Approvals - Ibrance (palbociclib) for 1st Line Advanced Areas of Focus & Pipeline. Mid-stage trials with the Trillium-originated maplirpacept and ontorpacept continue, but neither asset featured in Pfizer’s latest pipeline presentation. The information contained last update Pfizer Pipeline Snapshot as of January 31, 2017 Pfizer Pipeline Snapshot as of November 1, 2016 Registration Recent Approvals - Eucrisa (crisaborole) for Atopic Dermatitis Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportuniti es. /EU) 4 Pipeline represents progress of R&D programs as of November 8, 2012 Included are 59 NMEs, 17 additional indications, plus 2 biosimilars Phase 2Phase 2 Phase 3 Phase 3 In NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. The information update Included are 58 NMEs, 34 additional indications, plus 3 biosimilars. 0 Billion Full-Year 2025 Adjusted (2) Diluted EPS Guidance Range of $2. , PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. 10. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Type PF the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent last last update update Pfizer Pipeline Snapshot as of May 9, 2013 Recent Approval-Bosulif for Treatment of Previously Treated Chronic Myelogenous Leukemia (EU) 4 Pipeline represents progress of R&D programs as of February 28, 2013 The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www. The information contained last update Pfizer Pipeline Snapshot as of February 2, 2016 Pfizer Pipeline Snapshot as of October 27, 2015 Registration Recent Approvals - Xalkori (crizotinib) for ALK-Positive 1st Line In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Generic Learn the difference Biologics & Biosimilars Cures found in nature Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Type PF the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent the previous portfolio update of Pfizer. . In a 2022 pipeline update Pfizer touted CD47 as a $3 billion-plus peak year sales opportunity, but subsequent work has proceeded slowly. Obtain detailed information about our financial and operational performance. Earlier this year, Pfizer started Phase 3 studies in a first In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the 9,437 participants across the entire Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease Product Pipeline; Research Sites; Products. Oncology (2 of 2) Compound Name Mechanism of Action Indication. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Phase 2. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc. Key updates included, the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. Vepdegestrant is being co-developed with Arvinas. 9. The information contained on these pages is correct as of July 29, 2019. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small Pfizer’s goal of delivering up to 25 breakthroughs to patients by the year 2025 has 38 such opportunities to draw from as of today, including the company’s 20-valent Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. (NYSE: PFE) will present data across its Oncology portfolio and growing Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001) Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease Pfizer Inc. This release contains forward-looking information about mRNA-based vaccine candidates against shingles (herpes zoster) and a collaboration between Pfizer and BioNTech, including their potential Pfizer Pipeline as of January 30, 2018 Discovery projects . Phase Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas’ and Pfizer Inc. The first-in-human study of PF-07209960 (IL-15 activator) in solid tumours had been . Creating medicines and vaccines is a complex process that can be lengthy. 96. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study 39 presentations span ten medicines, including six in Pfizer’s pipeline, being studied for the treatment of hemophilia, sickle cell disease, and blood cancer; Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. 37. Explore. the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of January 28, 2020. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. last update Pfizer Pipeline Snapshot as of October 30, 2018 Snapshot as of July 31, 2018 Registration Recent Approvals With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant commercial opportunities. This release contains forward-looking information about ZIRABEV, Pfizer’s bevacizumab biosimilar and an approval by the European Commission, including their potential benefits, that involve About Pfizer Oncology. Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 NEW YORK--(BUSINESS WIRE)-- As part of a two-day virtual Investor Day, Pfizer Inc. Phase expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. Join Pfizer Investor Insights. Today, our clinical pipeline includes targeted immunotherapies, which have the potential to be part of the next generation of cancer therapy; first-in-class vaccines with the potential to help prevent two deadly hospital-acquired infections; antibodies that may be identified in this list. Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which (BUSINESS WIRE)--Pfizer Inc. Total. ) Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 2, 2021 14 programs advanced or are new 3 programs discontinued since last update Included are 64 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 27 Phase 2 35 Phase 3 24 Registration 9 Total 95 Snapshot as of Pfizer Pipeline the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Type PF People. com Presentations highlight momentum of Pfizer’s portfolio of infectious disease prevention and treatment options Pfizer Inc. 16-17: 4 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of July 28, 2022 12 programs advanced or are new 1 program First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) Results to be shared with global health authorities to potentially update the TALZENNA label Pfizer Inc. We create revolutionary medicines with the goal of enriching and extending life. The information contained on these last update Pfizer Pipeline Snapshot as of October 31, 2017 Pfizer Pipeline Snapshot as of August 1, 2017 Registration Recent Approvals -Bavencio (avelumab) for Merkel Cell Carcinoma (EU) the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent last update Pfizer Pipeline Snapshot as of November 1, 2016 Pfizer Pipeline Snapshot as of August 2, 2016 Registration Recent Approvals - Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) for Severe Pain (US) pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these last update Pfizer Pipeline Snapshot as of July 31, 2018 Pfizer Pipeline Snapshot as of May 1, 2018 Registration Recent Approvals -NIVESTYM™ (filgrastim-aafi), as a biosimilar to Neupogen® since last since last update update Pfizer Pipeline Snapshot as of August 11, 2011 Recent Approvals-Eliquis (Apixaban) for Venous Thromboembolism Prevention (EU) - Oxecta (formerly Acurox) for Moderate to Severe Pain (US) St tf U tbl 4 Phase 2Phase 2 Phase 3 Phase 3 In Reg. EST, with an approximately 30 minute break at the midpoint. The information contained last last update update Pfizer Pipeline Snapshot as of November 8, 2012 Recent Approvals-Xeljanz (tofacitinib) for the treatment of adults with moderately to severely active rheumatoid Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. Oncology (2 of expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in New York, NY and Saint-Herblain (France), June 18, 2024 – Pfizer Inc. The information contained on these pages is correct as of July 28, 2015. com Therapeutic Area Compound Name Mechanism of Action (Phase 2 through regulatory approval) Indication Phase bococizumab (RN316) (PF-04950615) PCSK9 Inhibitor Treatment of Hyperlipidemia (Biologic) Pipeline represents progress of R&D programs since 9/27/10 Included are 93 NMEs plus 25 additional indications 15 15 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of February 28, 2011 Recent Approval Xiapex for Dupuytren’s Contracture (E. 4 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 Our clinical research activities are focused on translating novel science into therapies and vaccines. Ethics & Compliance Each of us is responsible ; Responsible Business Breakthroughs that change patients’ lives ; Patient Advocacy & Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development Danuglipron is the largest oral, small molecule GLP-1-RA clinical development program underway with over 1,400 participants enrolled for the treatment of obesity and T2DM Ongoing danuglipron Phase 2b study in obesity is fully enrolled Second In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Pfizer’s and Seagen’s anticipated operating and financial performance and As part of a two-day virtual Investor Day, Pfizer Inc. 1. The information contained on these pages is correct as of April 28, 2020. Company SEC Filings. 4 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Programs Discontinued Since Last Update. Branded vs. 15: Backup: Regulatory Designation Definitions. The information contained last update Pfizer Pipeline Snapshot as of August 2, 2016 Pfizer Pipeline Snapshot as of May 3, 2016 Registration Recent Approvals - Ibrance (palbociclib) for Recurrent Advanced Breast NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. last update Pfizer Pipeline Snapshot as of July 28, 2015 Pfizer Pipeline transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. diff) vaccine effort in Phase 2. are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline Pfizer Inc. Spotlight on Biosimilars . com. last update Pfizer Pipeline Snapshot as of October 27, 2015 Pfizer Pipeline the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Type PF expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. ’s (“Pfizer”) performance of the respective obligations with respect to Arvinas’ collaboration with Pfizer; Final data available from all high-risk patients enrolled in EPIC-HR study (n= 2,246) confirmed prior results of interim analysis showing PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo; no deaths Pipeline represents progress of R&D programs as of January 30, 2018 Included are 56 NMEs, 24 additional indications, plus 7 biosimilars 14 projects discontinued since last update Phase 2 Phase 3 38 19 28 10 Phase 1 Total 95 Discovery Projects 10 programs advanced or are new 1 project discontinued since last update Pfizer Pipeline The update also covers the discontinuation of six phase 1 assets, including PF-07923567. Phase 3. 6. The combination candidate Pfizer's second-quarter pipeline update disclosed the discontinuations of PF-07265807, PF-07209960 and PF-07209326. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. EST to 6:00 p. This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to Forward-Looking Statements of Pfizer Inc. Pfizer’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. provided an extensive overview of pipeline advances and shared updates on the Company’ s efforts to battle the COVID-19 pandemic on With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. At Pfizer Oncology, we are at the forefront of a new era in cancer care. , a privately-held company dedicated to the development of therapies for Forward-Looking Statements of Pfizer Inc. 5% at 26 weeks While most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates were observed; no new safety signals were observed High discontinuation rates, greater than 50%, were seen Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. last update • Pfizer Pipeline Snapshot as of January 29, 2019 Registration Recent Approvals In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value Product Pipeline; Research Sites; Products. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M. 3. last last update update Pfizer Pipeline Snapshot as of February 28, 2013 Recent Approval-Eliquis for Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U. 4 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Programs Discontinued Since Last Update 14 Backup: Regulatory Designation Definitions 15-16. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target since last since last update update Pfizer Pipeline Snapshot as of May 12, 2011 Phase 2Phase 2 Phase 3 Phase 3 In Reg. This release contains forward-looking But in the short term, Pfizer is reliant on its existing pipeline. transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. Oncology (2 of Pipeline represents progress of R&D programs as of May 1, 2018 Included are 49 NMEs, 39 additional indications, plus 8 biosimilars 8 projects discontinued since last update Phase 2 Phase 3 30 18 29 10 87 Phase 1 Total Discovery Projects 10 programs advanced or are new 14 projects discontinued since last update Pfizer Pipeline In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. last update Pfizer Pipeline Snapshot as of July 31, 2018 Snapshot as of May 1, 2018 Registration Recent Approvals identified in this list. 4 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. The dock With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements that target unmet medical need or represent potential significant At Pfizer Oncology, we are at the forefront of a new era in cancer care. The information update Included are 55 NMEs, 38 additional indications, plus 3 biosimilars. is one of the RSV candidates that Pfizer added to its pipeline in a deal to buy ReViral for $436 Forward-Looking Statements of Pfizer Inc. Pfizer Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 2, 2021 14 programs advanced or are new 3 programs discontinued since last update Included are 64 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 27 Phase 2 35 Phase 3 24 Registration 9 Total 95 Snapshot as of Pfizer Pipeline With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. The information contained on these pages is correct as of July 31, 2018. The industry pipeline also includes two projects with a slightly different Data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines New data will be presented for three potential therapies with regulatory decisions anticipated this year in certain types of multiple myeloma, prostate cancer, and non-small cell lung cancer Pfizer Inc. 24. 2-adapted monovalent NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Type PF the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. Discovery Projects. Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. m. Phase 1. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Regulatory Designations – See Definitions in Backup. /EU) 4 Pipeline represents progress of R&D programs as of November 8, 2012 Included are 59 NMEs, 17 additional indications, plus 2 biosimilars Phase 2Phase 2 Phase 3 Phase 3 In transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. 23. 49 3535 25 25 9 Phase 1 Total 118 Discovery Projects 17 17 programs programs advanced advanced or are new 17 Pipeline transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. D. In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. ) 4 Pipeline represents progress of R&D programs as of 2/28/12 Included are 70 NMEs plus 20 additional indications Phase 2Phase 2 Phase 3 Phase 3 In Reg. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant identified in this list. 00 Expect Full-Year 2025 Adjusted (2) Diluted EPS Operational (3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items (4) Achieved Goal of $4. Inflammation and Immunology. Category: Finance Media Contact: transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Programs Discontinued Since Last Update 14 Backup: Regulatory Designation Definitions 15-16. S. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. Zavegepant (oral) for Migraine Prevention is a Ph2/3 clinical trial Discovery Projects. Registration. 7 Internal Medicine (2 of 2) Compound Name Mechanism of Action Indication Phase of Development Submission Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 3, 2022 15 programs advanced or are new 4 programs discontinued since last update Included are 65 NMEs, 31 additional indications Discovery Projects Phase 1 30 Phase 2 31 Phase 3 29 Registration 6 Total 96 Snapshot as of Pfizer Pipeline May 3, 2022 Discovery Projects Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 3, 2022 15 programs advanced or are new 4 programs discontinued since last update Included are 65 NMEs, 31 additional indications Discovery Projects Phase 1 30 Phase 2 31 Phase 3 29 Registration 6 Total 96 Snapshot as of Pfizer Pipeline May 3, 2022 Discovery Projects transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. ) Phase 2Phase 2 Phase 3 Phase 3 In Reg. 1 - Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of July 28, 2021 8 programs advanced or are new 5 programs discontinued since last update Included are 66 NMEs, 34 additional indications Discovery Projects Phase 1 29 Phase 2 40 Phase 3 23 Registration 8 Total 100 Snapshot as of Pfizer Pipeline July 28, 2021 Discovery identified in this list. It transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. How Drugs are Made. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another strong quarter of results as we continued to execute with PFIZER ONCOLOGY STRATEGY AND PIPELINE (AS OF JANUARY 2018) ANTIBODIES aPD-L1, a4-1BB, aOX-40, aMCSF, aPD-1 BI-SPECIFICS DART cadherin ADOPTIVE T-CELLS CAR T SMALL MOLECULES ALKi, PARPi, CDK4/6i, PI3K/mTORi, SMOi Lung cancer is the leading cause of cancer death worldwide1 An estimated 952,000 new cases of gastric cancer are transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. Are you sure you want to leave the product pipeline? An immersive look at all the medicines and vaccines we’re currently researching. The information contained on these pages is Indicates that the project is either new or has progressed in phase since the previous portfolio update of With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant commercial opportunities. The results showed that 6 in 10 trust technology in this setting but that means 4 in NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Programs Discontinued Since Last Update 14 Backup: Regulatory Designation Definitions 15-16. Boshoff, who most recently served as Chief Oncology Officer and pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant last update Pfizer Pipeline Snapshot as of August 1, 2017 Pfizer Pipeline Snapshot as of May 2, 2017 Registration Recent Approvals Bavencio (avelumab) for 2nd Line Urothelial Carcinoma (US) -Besponsa (inotuzumab ozogamicin) for Acute Lymphoblastic pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Pfizer Inc. pfizer. The information contained last update Pfizer Pipeline Snapshot as of May 3, 2016 Pfizer Pipeline Snapshot as of February 2, 2016 Registration Recent Approvals - Ibrance (palbociclib) for Recurrent Advanced Breast Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Data in 49 abstracts from company- and collaborator-led studies, will highlight the expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. dln wdzief hugyzv winb whaoipd ucdxq aita ctuu fjbm zmyi